BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 18677725)

  • 1. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany.
    Stargardt T; Schreyögg J; Busse R
    Health Policy; 2007 Nov; 84(1):30-8. PubMed ID: 17553587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current problems in assessing drug prices].
    Lucioni C
    Medicina (Firenze); 1989; 9(4):429-36. PubMed ID: 2634234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing and firms' pricing strategies.
    Miraldo M
    J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical promotion and GP prescription behaviour.
    Windmeijer F; de Laat E; Douven R; Mot E
    Health Econ; 2006 Jan; 15(1):5-18. PubMed ID: 15945041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elasticities of market shares and social health insurance choice in Germany: a dynamic panel data approach.
    Tamm M; Tauchmann H; Wasem J; Gress S
    Health Econ; 2007 Mar; 16(3):243-56. PubMed ID: 16981190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.